Sakarya University Faculty of Medicine, Deparment of Medical Microbiology, Sakarya, Turkey.
Sakarya University Faculty of Medicine, Deparment of Pulmonology, Sakarya, Turkey.
Int J Antimicrob Agents. 2022 Jan;59(1):106489. doi: 10.1016/j.ijantimicag.2021.106489. Epub 2021 Nov 27.
The aim of this study was to determine the in vitro efficacy of intravenous (IV) fosfomycin against extensively drug-resistant Enterobacterales strains and the effect of glucose 6-phosphate (G6-P) on sensitivity results.
Thirty-two extensively drug-resistant Klebsiella pneumonia strains were included in the study. Detection of the carbapenemase genes was performed using the Gene-Xpert® System Carba R® kit. Susceptibility of IV fosfomycin was assessed using the agar dilution method. The agar dilution method was repeated using Muller-Hinton Agar medium without G6-P to assess the effect of G6-P on sensitivity results.
All strains in the study produced carbapenemases and were resistant to all drugs tested, including carbapenems, piperacillin-tazobactam, ceftriaxone, and ceftazidime. Fosfomycin resistance was detected in 3 (9.3%) strains. When the sensitivity test was repeated without G6-P, fosfomycin resistance was detected in 82.7% of the fosfomycin-susceptible strains. The Gene-Xpert® System showed NDM-1 in 46.8%, OXA-48 in 18.7%, KPC in 3.1%, and NDM-1 + OXA-48 in 21.8% of the strains. OXA-48 was detected in one of the resistant strains, and none of the viable genes were detected in two of the resistant strains.
This study shows that IV fosfomycin is a potentially important treatment alternative for infections caused by common resistant strains. Accurate results may not be obtained unless G6-P is used in the agar dilution method for in vitro susceptibility studies of fosfomycin.
本研究旨在确定静脉注射(IV)磷霉素对广泛耐药肠杆菌科菌株的体外疗效,以及葡萄糖-6-磷酸(G6-P)对药敏结果的影响。
本研究纳入了 32 株广泛耐药肺炎克雷伯菌。使用 Gene-Xpert® System Carba R® 试剂盒检测碳青霉烯酶基因。采用琼脂稀释法评估 IV 磷霉素的敏感性。使用不含 G6-P 的 Muller-Hinton 琼脂培养基重复琼脂稀释法,以评估 G6-P 对药敏结果的影响。
研究中的所有菌株均产生碳青霉烯酶,对包括碳青霉烯类、哌拉西林-他唑巴坦、头孢曲松和头孢他啶在内的所有测试药物均耐药。3(9.3%)株检测出磷霉素耐药。当不添加 G6-P 重复药敏试验时,82.7%的磷霉素敏感菌株检测出磷霉素耐药。Gene-Xpert® 系统显示 46.8%的菌株携带 NDM-1,18.7%的菌株携带 OXA-48,3.1%的菌株携带 KPC,21.8%的菌株携带 NDM-1+OXA-48。在耐药菌株中检测到一株 OXA-48,在两株耐药菌株中未检测到任何存活基因。
本研究表明,IV 磷霉素是治疗常见耐药菌株感染的一种有潜力的重要治疗选择。除非在琼脂稀释法中使用 G6-P 进行磷霉素体外药敏研究,否则可能无法获得准确的结果。